fluticasone/salmeterol

DRUG13 trials

Sponsors

Boehringer Ingelheim, Gelb, Arthur F., M.D., AstraZeneca, University of Dundee, University of Rostock

Conditions

AsthmaChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveSmoke-related Lung Diseases

Phase 1

Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers

CompletedNCT00908362

University of RostockChronic Obstructive Pulmonary Disease, Smoke-related Lung Diseases

Start: 2009-05-31End: 2009-12-31Target: 45Updated: 2010-01-13

Phase 2

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

RecruitingNCT06676319

Start: 2024-11-07End: 2027-10-15Target: 1147Updated: 2026-03-24

Phase 3

Symbicort Onset of Action 2

CompletedNCT00646009

AstraZenecaAsthma

Start: 2003-03-31End: 2003-08-31Target: 48Updated: 2011-01-24

QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01315249

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease (COPD)

Start: 2011-03-31End: 2012-03-31Updated: 2013-08-09

A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149

CompletedNCT01709903

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease

Start: 2012-11-30End: 2014-02-28Updated: 2015-03-17

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

WithdrawnNCT01834885

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease

Start: 2013-12-31End: 2014-09-30Updated: 2013-11-11

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

WithdrawnNCT01860066

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease

Start: 2013-12-31End: 2014-09-30Updated: 2013-11-11

Phase 4

Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD

CompletedNCT00530842

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2007-09-30Updated: 2013-12-24

Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma

CompletedNCT00830505

University of DundeeAsthma

Start: 2009-04-30End: 2010-05-31Updated: 2019-05-08

Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01186653

Hull University Teaching Hospitals NHS TrustChronic Obstructive Pulmonary Disease

Start: 2007-10-31End: 2010-05-31Updated: 2010-09-06

Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol

TerminatedNCT02491970

Mundipharma Korea LtdAsthma

Start: 2015-08-31End: 2017-05-31Updated: 2018-05-16

Unknown Phase

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

RecruitingNCT00576069

Gelb, Arthur F., M.D.Asthma

Start: 2007-10-25End: 2027-06-30Target: 60Updated: 2023-10-26

Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway

CompletedNCT01231230

University of MiamiAsthma

Start: 2007-05-31End: 2010-08-31Updated: 2016-06-30

Related Papers

Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.

2017-11-2927 citations

Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal.

2016-10-017 citations

Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study

COPD Journal of Chronic Obstructive Pulmonary Disease2016-08-114 citations

QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE Studies

Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation2014-01-018 citations

Fluticasone impact on airway dendritic cells in smokers: a randomized controlled trial.

2013-10-297 citations

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.

2012-12-06224 citations

Effect of combination treatment on lung volumes and exercise endurance time in COPD.

2012-06-2819 citations

Acute effects of salmeterol and fluticasone propionate alone and in combination on airway blood flow in patients with asthma.

2011-10-066 citations

Fluticasone/Salmeterol combination confers benefits in people with asthma who smoke.

2011-06-0237 citations

Increased nitric oxide concentrations in the small airway of older normal subjects.

2010-08-1225 citations